Risk factors for a first thrombotic event in antiphospholipid antibody carriers. A multicentre, retrospective follow-up study

Annals of the Rheumatic Diseases

Volumn 68, Issue 3, 2009, Pages 397-399

  Ruffatti, A ^a,j   Del Ross, T ^a   Ciprian, M ^a   Nuzzo, M ^b   Rampudda, M ^a   Bertero, M T ^c   Bergia, R ^c   Caramaschi, P ^d   Biasi, D ^d   Capsoni, F ^e   Montaguti, L ^f   Ruffini, R ^f   Brucato, A ^g   Picillo, U ^h   Fanelli, V ^e   Riccieri, V ⁱ   Piccoli, A ^a   Valesini, G ⁱ   Doria, A ^a   Meroni, P L ^e   Tincani, A ^b   more..

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY OF BRESCIA   (Italy)

^c MAURIZIANO HOSPITAL   (Italy)

^d UNIVERSITY OF VERONA   (Italy)

^e UNIVERSITY OF MILAN   (Italy)

^f BUFALINI HOSPITAL   (Italy)

^g Bergamo Hospital   (Italy)

^h UNIVERSITY OF NAPLES FEDERICO II   (Italy)

ⁱ SAPIENZA UNIVERSITY OF ROME   (Italy)

^j UNIVERSITY HOSPITAL OF PADOVA   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CARDIOLIPIN ANTIBODY; HEPARIN; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; LUPUS ANTICOAGULANT; PHOSPHOLIPID ANTIBODY; WARFARIN;

ADULT; AGED; ANTIBODY TITER; ARTERY THROMBOSIS; ARTICLE; AUTOIMMUNE DISEASE; CARDIOVASCULAR RISK; CLINICAL ASSESSMENT; DEEP VEIN THROMBOSIS; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; IMMUNOGLOBULIN BLOOD LEVEL; LABORATORY TEST; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; THROMBOCYTOPENIA; THROMBOSIS; THROMBOSIS PREVENTION;

ADOLESCENT; ADULT; AGED; ANTIBODIES, ANTICARDIOLIPIN; ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; EPIDEMIOLOGIC METHODS; FEMALE; HETEROZYGOTE; HUMANS; HYPERTENSION; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; THROMBOSIS; YOUNG ADULT;

EID: 61449186513     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2008.096669     Document Type: Article

References (14)

1. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006;4:295-306.
2. Ginsburg KS, Liang MH, Newcomer L, Goldhaber SZ, Schur PH, Hennekens CH, et al. Anticardiolipln antibodies and the risk for ischemic stroke and venous thrombosis. Ann Intern Med 1992;117:997-1002.
3. Finazzi G, Brancaccio V, Mola M, Ciavarella N, Mazzucconi G, Schinco PC, et al. Natural history and risk factors for thrombosis In 360 patients with antiphospholipld antibodies: a four-year prospective study from the Italian Registry. Am J Med 1996;100:530-6.
4. Vaarala O, Mänttäri M, Manninen V, Tenkanen L, Puurunen M, Aho K, et al. Anticardiolipln antibodies and risk of myocardial infarction in a prospective cohort of middle-aged men. Circulation 1995;91:23-7.
5. Silver RM, Draper ML, Scott JR, Lyon JL, Reading J, Branch DW. Clinical consequences of antiphospholipld antibodies: an historic cohort study. Obostet Gynecol 1994;83:372-7.
6. Shah NM, Khamashta MA, Atsumi T, Hughes GRV. Outcome of patients with anticardiolipin antibodies: a 10 year follow-up of 52 patients. Lupus 1998;7:3-6.
7. Erkan D, Merrill JT, Yazici Y, Sammaritano L, Buyon JP, Lockshin MD. High thrombosis rate after fetal loss antiphospholipid syndrome: effective prophylaxis with aspirin. Arthritis Rheum 2001;44:1466-9.
8. Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette JC, et al. International consensus statement on preliminary classification criteria for definite antiphospholipld syndrome. Arthritis Rheum 1999;42:309-11.
9. Brandt JT, Triplett DA, Alving B, Scharrer I. Criteria for the diagnosis of lupus anticoagulants: an update. Thromb Haemost 1995;74:185-90.
10. Erkan D, Yazici Y, Peterson MG, Sammaritano L, Lockshin MD. A cross-sectional study of clinical thrombotic risk factors and preventive treatments In antiphospholipld syndrome. Rheumatology (Oxford) 2002;41:924-9.
11. Girón-Gonzáles JA, García Del Río E, Rodríguez C, Rodrígues-Martorell J, Serrano A. Antiphospholipld syndrome and asymptomatic carriers of antiphospholid antibodies: prospective analysis of 404 individuals. J Rheumatol 2004;31:1560-7.
12. De Groot PG, Lutters B, Derksen RHWM, Lisman T, Meyers JCM, Rosendaal FR. Lupus anticoagulants and the risk of a first episode of deep venous thrombosis. J Thromb Haemost 2005;3:1993-7.
13. Wahl DG, Bounameaux H, de Moerloose P, Sarasin FP. Prophylactic antithrombotic therapy for patients with systemic lupus erythmatosus with or without antiphospholipld antibodies: do the benefits outweigh the risk? A decision analysis. Arch Intern Med 2000;160:2042-8.
14. Erkan D, Harrison MJ, Levy R, Peterson M, Petri M, Sammaritano L, et al. Aspirin for primary thrombosis prevention In the antiphospholipld syndrome. Arthritis Rheum 2007;56:2382-91.